About ZAI LAB Company

Zaiding Pharmaceutical is an innovative biopharmaceutical company based in China and operating globally. It is committed to providing patients in China and around the world with innovative drugs in the fields of cancer, autoimmunity and infectious diseases. Zaiding Pharmaceutical is headquartered in Shanghai. Since its establishment in 2014, it has established partnerships with many of the world's leading biopharmaceutical companies to create a broad product line of late-stage innovative drug candidates. For global biopharmaceutical companies seeking to enter the Chinese market and find long-term Global Strategy partners for international clinical development, Zaiding Pharmaceutical has become one of the most trustworthy partner candidates in the industry with a series of successful cooperation cases. Through these successful collaborations, Zaiding Pharmaceutical has built the strongest advanced cancer product pipeline among innovative Chinese biotech companies, with several first-in-class and/or best-in-class drugs in the world. At the same time, we are continuously improving our internal R&D capabilities to further supplement our product line. The goal is to have 1-2 global new drug clinical trial applications (INDs) each year in the future. Zaiding Pharmaceuticals is rapidly developing into a fully integrated biopharmaceutical company that discovers, develops, produces and commercializes innovative drugs in China and around the world. To this end, we have set up an internal R&D center in China to promote drug research and development, built a strong clinical development and operation team, and established our own production base. In addition, we have set up a specialized commercial team to support the promotion of innovative products in China. We believe this integrated strategy will bring a sustainable competitive advantage to Zaiding Pharmaceuticals. Zaiding Pharmaceutical was successfully listed on the US NASDAQ in September 2017. Since then, the company has developed rapidly. It has set up branches or offices in many parts of China, and established the US headquarters in San Francisco in December 2018. As of December 2019, the company had approximately 700 employees worldwide.